FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

246 letters match. Newest first.

  1. International Laboratories Corp

    FDA warned International Laboratories Corp, a Thai drug manufacturer, over fabricated lab records and inadequate CGMP controls.

    High risk
  2. Aspen Pharmacare Holdings Limited

    FDA warns Aspen subsidiary over sterile OTC drug manufacturing failures including impurity testing, aseptic practices, data integrity, and environmental monitoring.

    High risk
  3. Rite-Kem Incorporated

    FDA warned Rite-Kem over inadequate current good manufacturing practice testing of over-the-counter drugs, including hand sanitizers and antimicrobial products.

    High risk
  4. Linghai ZhanWang Biotechnology Co., Ltd

    Linghai ZhanWang Biotechnology's OTC drugs, including antimicrobial wipes, fail manufacturing quality rules; FDA cites missing tests.

    High risk
  5. Wuhu Nuowei Chemistry Co., Ltd.

    FDA cited Wuhu Nuowei Chemistry for API CGMP deviations in impurity testing, stability data, and cleaning, and placed products on import alert.

    High risk
  6. BioStem Life Sciences

    FDA says BioStem Life Sciences made unapproved umbilical cord and amniotic products with significant CGMP violations.

    High risk
  7. Global Calcium Pvt. Limited

    FDA cites Global Calcium API plant for falsified records, deleted files, facility leaks and incomplete impurity profiles; products on Import Alert 66-40.

    High risk
  8. INCELL Corporation LLC

    FDA warned INCELL Corporation for making an unapproved amniotic-fluid drug without validating its sterile manufacturing process.

    High risk
  9. XO Biologix, LLC

    XO Biologix markets MaviX, an amniotic-fluid product, as an unapproved new drug and unlicensed biologic.

    High risk
  10. Sombra Cosmetics, Inc.

    FDA warned Sombra Cosmetics of OTC drug CGMP violations, including inadequate water controls and component testing.

    High risk
  11. Brands International Corporation

    Brands International, a Canadian drug manufacturer, limited an FDA inspection and had manufacturing quality violations including mold contamination.

    High risk
  12. Micro Orgo Chem

    Micro Orgo Chem in India failed CGMP for API drugs, including cleaning, process validation, stability and records.

    High risk
  13. Dr. Brite, LLC

    FDA cited Dr. Brite for manufacturing quality failures and selling unapproved, misbranded oral care and hand sanitizer drugs.

    High risk
  14. LCC Ltd.

    FDA warned LCC Ltd. over manufacturing-quality failures, contamination testing gaps, discarded lab data, and unapproved mouthwash drugs.

    High risk
  15. Catwalk Cosmetic Laboratories Pty Ltd.

    FDA warns South African over-the-counter drug maker Catwalk Cosmetic Laboratories of current good manufacturing practice violations and import alert.

    High risk
  16. Hangzhou Huiji Biotechnology Co., Ltd.

    FDA warned Hangzhou Huiji Biotechnology over CGMP failures in OTC hand sanitizers, including missing glycerin and ethanol safety tests.

    High risk
  17. Originitalia SRL

    FDA warns Originitalia SRL over manufacturing quality failures in OTC drugs, including untested active ingredient and missing release testing.

    High risk
  18. Tianjin Darentang Jingwanhong Pharmaceutical Co., Ltd.

    FDA cited Tianjin Darentang Jingwanhong Pharmaceutical for limiting a drug inspection and manufacturing violations at its China plant.

    High risk
  19. Choice All Natural, Inc. dba Om Botanical

    FDA warns Om Botanical of Apex, NC over filthy manufacturing, an unapproved rash cream, and lapsed FDA registration.

    High risk
  20. Soliteint Kozmetikai KFT

    Hungarian contract maker Soliteint Kozmetikai failed to test OTC pain-relief drugs and ingredients, FDA says; U.S. production halted.

    High risk
  21. Amnio Technology, LLC

    FDA warned Amnio Technology over unapproved injectable amniotic products and serious manufacturing deviations at its Phoenix facility.

    High risk
  22. Little Moon Essentials, LLC

    FDA warns Little Moon Essentials over CGMP failures and unapproved topical analgesic drugs made in Dania Beach, Florida.

    High risk
  23. Diamond Chemical Co., Inc.

    Diamond Chemical Co. in East Rutherford, NJ, made OTC hand sanitizers without required ingredient and finished-product testing or process validation.

    High risk
  24. Clean Solutions LLC

    FDA warned Clean Solutions LLC that its OTC hand soaps and sanitizer were adulterated because it released drugs without component or finished-product testing.

    High risk
  25. Azurity Pharmaceuticals, Inc.

    FDA warned Azurity Pharmaceuticals over unapproved FIRST drug kits and manufacturing quality failures at its Wilmington, MA plant.

    High risk
  26. Aromas Para El Alma S.A.

    Aromas Para El Alma, a Costa Rica drug manufacturer, made EREWHON hand sanitizer/spray subpotent and broke manufacturing rules.

    High risk
  27. EnviroServe Chemicals & Cleaners Ltd.

    EnviroServe's SOPURE hand sanitizer had manufacturing-quality violations and was sold as an unapproved, misleadingly labeled drug.

    High risk
  28. Orean Personal Care Ltd.

    FDA warned Orean Personal Care Ltd. that repeat manufacturing failures make its OTC drugs adulterated.

    High risk
  29. Regenerative Processing Plant, LLC

    FDA warns Regenerative Processing Plant over unapproved, misbranded Regener-Eyes eye drops and serious sterile manufacturing violations.

    High risk
  30. LS Promotions Inc.

    LS Promotions Inc. failed to adequately test and validate its OTC sunscreens, lip balm and hand sanitizer, making them adulterated drugs.

    High risk
  31. Nowrez & Ismail Shukri Company

    FDA warns Jordanian OTC drug maker Nowrez & Ismail Shukri over CGMP violations and import alert.

    High risk
  32. Omega Tech Labs LLC

    Omega Tech Labs in Boise, Idaho, released microbially contaminated combination drug-device product and failed manufacturing rules.

    High risk
  33. Genuine Virgin Aloe Corp dba Triderma

    FDA warned Triderma, an Anaheim OTC skin cream maker, of CGMP violations after a January 2024 inspection.

    High risk
  34. Yahon Enterprise Co., Ltd.

    FDA warned Yahon Enterprise over manufacturing quality failures for OTC antiseptic wipes after a December 2023 inspection.

    High risk
  35. Max Chemical Inc.

    FDA warned Max Chemical Inc. in San Juan, Puerto Rico, that its OTC drug manufacturing violated CGMP, making its drugs adulterated.

    High risk
  36. ARG Laboratories, Inc.

    FDA found ARG Laboratories released failing over-the-counter drug lots, lacked manufacturing controls, and marketed two unapproved pain creams.

    High risk
  37. reBom Co., Ltd.

    reBom failed current good manufacturing practice for OTC drugs, including inadequate stability and component testing.

    High risk
  38. Optikem International Inc.

    FDA warns Optikem International after inspection found inadequate aseptic controls for sterile ophthalmic drugs, including contamination and validation failures.

    High risk
  39. Laboratorio Magnachem International

    FDA cited Laboratorio Magnachem for CGMP failures and unapproved, misbranded Broncochem cough/cold drugs after a 2023 inspection.

    High risk
  40. Sani-Care Salon Products, Inc.

    FDA warns Sani-Care Salon Products over CGMP failures in hand sanitizer manufacturing, including inadequate quality oversight and testing.

    High risk
  41. GFA Production Xiamen Co., Ltd.

    GFA Production Xiamen failed CGMP for drugs, including process validation, cleaning, and lab controls.

    High risk
  42. Aqualex Co., Ltd.

    Aqualex, a Korean contract manufacturer, was cited for manufacturing failures and an unapproved OTC sunscreen with misleading labeling.

    High risk
  43. Neobiosis, LLC

    FDA warns Neobiosis over unapproved amniotic fluid and umbilical cord products and serious manufacturing quality failures.

    High risk
  44. TCT Nutraceuticals SDN. BHD

    FDA warns TCT Nutraceuticals over manufacturing-rule failures in OTC hand sanitizer, including no methanol testing.

    High risk
  45. Cosmetic Solutions, LLC

    FDA warns Cosmetic Solutions over manufacturing failures and unapproved OTC drugs at Boca Raton plant.

    High risk
  46. Aruba Aloe Balm N.V.

    Aruba Aloe Balm N.V. made OTC drugs with methanol-contaminated ethanol and failed CGMP, prompting recall and import alert.

    High risk
  47. Global Cosmetics Company Limited

    FDA warns Global Cosmetics over manufacturing quality failures in OTC hand sanitizer, including no methanol testing of ethanol.

    High risk
  48. Master Paints & Chemicals Corp.

    FDA warned Master Paints & Chemicals Corp. over inadequate testing and quality oversight for OTC drugs including hand sanitizer.

    High risk
  49. Kilitch Healthcare India Limited

    FDA warns Kilitch Healthcare India over insanitary sterile drug manufacturing and falsified environmental monitoring data.

    High risk
  50. Antaria Pty. Ltd.

    FDA warned Antaria Pty. Ltd. about manufacturing quality failures in its active drug ingredient, including poor out-of-specification investigations and testing.

    High risk